OncologyTube Professional - Patients Click Here
1,538,090 video views
Loading........
Description: Earn CME credit: https://www.naccme.com/prog...

PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use ...
50:21
Earn CME credit: https://www.... PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have expanded in recent months. This roundtable discussion between Dr. Robert L. C...
by:imedex | 30 views
25:28
Earn CME Credit: https://www.... Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopeni​c purpura (ITP), and there remains significant variability in clinical practice patterns for its management. This activity features Drs. David P. Steensma and Ilene C. Weitz sharing their insights about data rec...
by:imedex | 11 views
40:26
Earn CME credit for this activity: https://www.... With a focus on integrating recent advances into improved care pathways, this on-demand webcast features a presentation on the latest treatment options, current guidelines, available cost data, and expert recommendation...
by:imedex | 278 views
37:22
Earn CME credit for this activity: https://www.... This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway pl...
by:imedex | 344 views
52:19
Earn CME credit for this activity: https://www.... This on-demand webcast examines the latest clinical and pharmacoeconomi​c data surrounding emerging therapies in AML, including novel chemotherapy formulations, FLT3 inhibitors, and IDH inhibitors for informed pathway pl...
by:imedex | 327 views
29:50
Earn CME credit for this activity: https://www.... This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-class differences in the mechanisms of action, efficacy and safety, and indications of available and...
by:imedex | 260 views
40:05
Earn CME credit for this activity: https://www.... This on-demand webcast examines recent clinical trial data for novel and emerging therapies, including doublet and triplet combinations for relapsed/refrac​tory disease, and discusses how best to integrate recent therapeutic advances into clinical pathways. © 2018 NA...
by:imedex | 327 views
01:14
Koen Van Besien, M.D. Director of the Stem Cell Transplant Program, Professor of Medicine at Weill Cornell Medical College Discusses CAR T Cell Therapy Or Transplant at Lymphoma & Myeloma on October 18, 2018.
by:imedex | 518 views
01:37
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses The Roll Of Chemotherapy In CLL at Lymphoma & Myeloma on October 18, 2018.
by:imedex | 263 views
01:22
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses Ibrutinib Or Chemotherapy at Lymphoma & Myeloma on October 18, 2018.
by:imedex | 286 views

About imedex
Description: Imedex® has provided the best in accredited, independent continuing medical education for over 25 years. We develop high quality, scientific programs that translate the latest research into clinically relevant information. The programs have a proven sustained impact on disease management, exceptional organization, and outstanding educational value. Imedex is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality, scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management. Our programs focus on improving patient care around the world. With over 50,000 e-learning experiences annually and more than 102,000 live meeting attendees since 2001, Imedex truly educates the global healthcare community. At Imedex, we believe that education is the best medicine.

Links
Channel Url:

Social Links: